| Ident. | Authors (with country if any) | Title |
|---|
| 000013 (2013) |
Micha Levi [États-Unis] ; Susan Grange [États-Unis] ; Nicolas Frey [Suisse] | Exposure‐Exposure Relationship of Tocilizumab, an Anti–IL‐6 Receptor Monoclonal Antibody, in a Large Population of Patients With Rheumatoid Arthritis |
| 000016 (2009) |
Mao Mao An [République populaire de Chine] ; Zui Zou [République populaire de Chine] ; Hui Shen [République populaire de Chine] ; Jun Dong Zhang [République populaire de Chine] ; Yong Bing Cao [République populaire de Chine] ; Yuan Ying Jiang [République populaire de Chine] | The addition of tocilizumab to DMARD therapy for rheumatoid arthritis: a meta-analysis of randomized controlled trials |
| 000066 (2013) |
Kanae Tani [Japon] ; Risa Takayanagi [Japon] ; Haruko Yokoyama [Japon] ; Yasuhiko Yamada [Japon] | Theoretical analysis of efficacy of biological agent for rheumatoid arthritis based on target molecular binding occupancy |
| 000088 (2011) |
Emily Beth Devine [États-Unis] ; Rafael Alfonso-Cristancho [États-Unis] ; Sean D. Sullivan [États-Unis] | Effectiveness of Biologic Therapies for Rheumatoid Arthritis: An Indirect Comparisons Approach |
| 000105 (2012) |
M. Gallego-Galisteo ; A. Villa-Rubio ; E. Alegre-Del Rey [Espagne] ; E. Márquez-Fernández ; J. J. Ramos-Báez | Indirect comparison of biological treatments in refractory rheumatoid arthritis |
| 000228 (2012) |
Tomoyuki Imagawa [Japon] ; Syuji Takei [Japon] ; Hiroaki Umebayashi [Japon] ; Kenichi Yamaguchi [Japon] ; Yasuhiko Itoh [Japon] ; Toshinao Kawai [Japon] ; Naomi Iwata [Japon] ; Takuji Murata [Japon] ; Ikuo Okafuji [Japon] ; Mari Miyoshi [Japon] ; Yasuhiro Onoe [Japon] ; Yoshifumi Kawano [Japon] ; Noriko Kinjo [Japon] ; Masaaki Mori [Japon] ; Neelufar Mozaffarian [États-Unis] ; Hartmut Kupper [Allemagne] ; Sourav Santra [Inde] ; Gina Patel [États-Unis] ; Shinichi Kawai [Japon] ; Shumpei Yokota [Japon] | Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan |
| 000461 (2011) |
Alberto Migliore [Italie, Espagne] ; Emanuele Bizzi [Italie] ; Serena Broccoli [Italie] ; Bruno Laganà [Italie] | Indirect comparison of etanercept, infliximab, and adalimumab for psoriatic arthritis: mixed treatment comparison using placebo as common comparator |
| 000681 (2008) |
Rhonda Siddall | An overview of the clinical trial data presented at the 44th American Society of Clinical Oncology Annual Meeting (ASCO) and the 9th Annual European Congress of Rheumatology (EULAR) |
| 000875 (2012) |
Nicolino Ruperto [Italie] ; Pierre Quartier [France] ; Nico Wulffraat [Pays-Bas] ; Patricia Woo [Royaume-Uni] ; Angelo Ravelli [Italie] ; Richard Mouy [France] ; Brigitte Bader-Meunier [France] ; Sebastiaan J. Vastert [Pays-Bas] ; Emanuele Noseda [Suisse] ; Daniele D'Ambrosio [Suisse] ; Jean Lecot [Suisse] ; Abhijit Chakraborty [Suisse] ; Alberto Martini [Italie] ; Andrea Chioato [Suisse] | A phase II, multicenter, open‐label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features |
| 000950 (2014) |
Masami Tanaka [Japon] ; Masako Kinoshita [Japon] | Congress report of the 2014 American Academy of Neurology annual meeting |
| 000A51 (2013) |
Christian Gissel [Allemagne] ; Holger Repp [Allemagne] | Cost per responder of TNF-α therapies in Germany |
| 000B44 (2012) |
W. Rigby [États-Unis] ; H. Tony [Allemagne] ; K. Oelke [États-Unis] ; B. Combe [France] ; A. Laster [États-Unis] ; C. A. Von Muhlen [Brésil] ; E. Fisheleva [Royaume-Uni] ; C. Martin [Royaume-Uni] ; H. Travers [Royaume-Uni] ; W. Dummer [États-Unis] | Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a forty‐eight–week randomized, double‐blind, placebo‐controlled, parallel‐group phase III trial |
| 000B67 (2012) |
Sandeep Kumar [États-Unis] ; Mark A. Mitchell [États-Unis] ; Bonita Rup [États-Unis] ; Satish K. Singh [États-Unis] | Relationship between potential aggregation‐prone regions and HLA‐DR‐binding T‐cell immune epitopes: Implications for rational design of novel and follow‐on therapeutic antibodies |
| 000C71 (2011) |
G. Dückers [Allemagne] ; T. Niehues [Allemagne] | Rheuma bei Kindern und Jugendlichen |
| 000E59 (2011) |
Takeshi Kuroda [Japon] ; Naohito Tanabe [Japon] ; Daisuke Kobayashi [Japon] ; Hiroe Sato [Japon] ; Yoko Wada [Japon] ; Shuichi Murakami [Japon] ; Masaaki Nakano [Japon] ; Ichiei Narita [Japon] | Association between clinical parameters and amyloid-positive area in gastroduodenal biopsy in reactive amyloidosis associated with rheumatoid arthritis |
| 000E83 (2012) |
Makio Kusaoi [Japon] ; Ken Yamaji ; Go Murayama ; Misa Yasui ; Risa Yamada ; Ruka Hishinuma ; Takuya Nemoto ; Katsura Hohtatsu ; Michiaki Kageyama ; Toshio Kawamoto ; Kaoru Sugimoto ; Fumio Sekiya ; Takayuki Kon ; Michihiro Ogasawara ; Kazuo Kempe ; Hiroshi Tsuda [Japon] ; Yoshinari Takasaki | Gene Expression Analysis Using a High‐Resolution DNA Microarray of Peripheral Whole Blood Immediately Before and After Leukocytapheresis for Rheumatoid Arthritis |
| 001218 (2012) |
P. A. Marichal-Gallardo [Mexique] ; M. M. Álvarez [Mexique] | State‐of‐the‐art in downstream processing of monoclonal antibodies: Process trends in design and validation |
| 001232 (2011) |
Liisa M. Virkki [Finlande] ; Heikki Valleala [Finlande] ; Yuya Takakubo [Finlande] ; Jorma Vuotila [Finlande] ; Heikki Relas [Finlande] ; Riitta Komulainen [Finlande] ; Riitta Koivuniemi [Finlande] ; Urpo Yli-Kerttula [Finlande] ; Markku Mali [Finlande] ; Susanna Sihvonen [Finlande] ; Maija-Liisa Krogerus [Finlande] ; Eero Jukka [Finlande] ; Satu Nyrhinen [Finlande] ; Yrjö T. Konttinen [Finlande] ; Dan C. Nordström [Finlande] | Outcomes of switching anti-TNF drugs in rheumatoid arthritis—a study based on observational data from the Finnish Register of Biological Treatment (ROB-FIN) |
| 001247 (2012) |
P. P. Tak [Pays-Bas] ; P. J. Mease [États-Unis] ; M. C. Genovese [États-Unis] ; J. Kremer [États-Unis] ; B. Haraoui [Canada] ; Y. Tanaka [Japon] ; C. O. Bingham Iii [États-Unis] ; A. Ashrafzadeh [États-Unis] ; H. Travers [Royaume-Uni] ; S. Safa-Leathers [Royaume-Uni] ; S. Kumar [Royaume-Uni] ; W. Dummer [États-Unis] | Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: Results of a forty‐eight–week randomized, double‐blind, placebo‐controlled, parallel‐group phase III trial |
| 001255 (2012) |
Muhammad Sajid Hamid Akash [République populaire de Chine] ; Qi Shen [République populaire de Chine] ; Kanwal Rehman [République populaire de Chine] ; Shuqing Chen [République populaire de Chine] | Interleukin‐1 receptor antagonist: A new therapy for type 2 diabetes mellitus |
| 001263 (2012) |
Michael Yellin [États-Unis] ; Igor Paliienko [Ukraine] ; Andra Balanescu [Roumanie] ; Semen Ter-Vartanian [Ukraine] ; Vira Tseluyko [Ukraine] ; Li-An Xu [États-Unis] ; Xiaolu Tao [États-Unis] ; Pina M. Cardarelli [États-Unis] ; Heidi Leblanc [États-Unis] ; Geoff Nichol [États-Unis] ; Codrina Ancuta [Roumanie] ; Rodica Chirieac [Roumanie] ; Allison Luo [États-Unis] | A phase II, randomized, double‐blind, placebo‐controlled study evaluating the efficacy and safety of MDX‐1100, a fully human anti‐CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis |
